Proportions of CD16+ as well as the combination of CD16+ and CD16-CD103+ subsets positively correlated with the overall proportions of TI-NK cells in breast tumor infiltrates (Fig. 4F), indirectly supporting the association between the presence of CD16+ and CD16-CD103+ NK cells with the efficacy of anti-HER2 antibody-based neoadjuvant treatment. This evidence concerns the gene ITGAE and breast neoplasm.